Summary

• Ministers reportedly favour extending the NHS Federated Data Platform contract, but no final decision has been announced.
• The initial contract term ends in March 2027, with the decision on extension required by December 2026.
• The review must weigh continuity across 142 NHS trusts against supplier dependence, contested benefit claims, and public trust.

The UK government is preparing to extend Palantir‘s NHS Federated Data Platform contract rather than replace the supplier when the agreement’s initial term ends in March 2027, according to reporting that points towards continuity while ministers consider a different approach to the next procurement.

The existing agreement, awarded to a Palantir-led consortium in November 2023, has an estimated value of £330 million over its potential seven-year duration. Its initial three-year term began in March 2024, with options for further extensions. The government must decide by December 2026 whether to continue beyond March 2027.

The Financial Times reported on 5 November that ministers favour an extension of approximately two years, allowing time to develop a future competition that could support greater UK technological capability and reduce dependence on a single supplier. That remains a reported intention rather than an announced contract decision.

At a parliamentary committee hearing on 4 November, Health Secretary Yvette Cooper said the contract review was still under way and declined to comment on its outcome. She confirmed that the government was following the contractual review process and considering the wider requirements of digital healthcare systems.

Replacing the platform involves operational risk

The Federated Data Platform connects information held in different NHS systems so that participating organisations can manage waiting lists, plan hospital capacity, coordinate discharges, and analyse operational performance. It operates as an additional data layer rather than replacing the underlying clinical and administrative systems.

Each participating trust or integrated care board controls its own instance of the platform, while NHS England maintains a national instance for appropriate planning and analytical purposes. The arrangement allows information from separate systems to be used together without creating a single central database containing every patient record.

As of August 2026, 142 of England’s 202 NHS acute, mental health, community, and ambulance trusts were using the platform operationally. Another 28 had signed memoranda of understanding but had not yet reached live operational use, while 35 of 36 integrated care boards were also using the system.

That level of adoption makes a supplier change more demanding than replacing software used by a single department. A successor would need to support existing data interfaces, application functions, access controls, and operational workflows while maintaining services on which hospital teams have begun to rely.

The contract contains provisions intended to support exit planning and portability, and NHS England maintains that the arrangements are designed to prevent supplier lock-in. However, contractual rights to software and data do not establish how quickly the complete platform could be transferred into a different operating environment.

Applications built using Palantir’s Foundry technology may require changes to their supporting services before they can operate on another supplier’s platform. The extent of that work depends on how the applications were developed and which components are specific to the current environment.

A transition would also need to address staff training, testing, service assurance, and the ability to recover from failures. Hospital planning systems cannot simply be suspended during a migration, making continuity a central procurement consideration.

Benefit claims require stronger evidence

The government’s review extends beyond the question of whether Palantir can continue providing the service. Ministers and parliamentary committees have also examined the evidence that the platform is delivering the operational improvements attributed to it.

NHS England has published examples of improvements in surgical scheduling, capacity planning, and patient flow, although its statistical reporting now makes clear that observed changes cannot automatically be attributed to the platform. Other operational factors may have contributed, and the available analysis does not establish direct cause and effect.

In July 2026, the Office for Statistics Regulation welcomed additional caveats introduced by NHS England after concerns about how platform benefits had been communicated. An independent evaluation commissioned from Imperial College Projects is expected to be published after the contract extension decision.

During the 4 November committee hearing, NHS England chief executive Sir Jim Mackey said he intended to write to Palantir asking it to clear future claims about platform benefits with NHS England before publication. He also indicated that enforcing such an expectation contractually could be difficult.

The distinction between platform use and demonstrated improvement is commercially important. An organisation may adopt a system because it provides useful functionality without being able to prove that every improvement in performance resulted from the technology.

Hospitals also differ in digital maturity. Trusts with relatively limited existing analytical capabilities may gain more from a common platform than organisations already operating sophisticated local systems. Any future procurement will need to account for those differences rather than assuming that a single implementation produces identical results everywhere.

Trust and sovereignty influence the review

Public trust remains a separate consideration. Parliamentary committees and campaign groups have questioned Palantir’s suitability as an NHS supplier because of its wider government and defence work, while concerns have also been raised about how patient information is accessed and governed.

NHS England states that organisations retain control of their data and that contractual restrictions apply to its use. The National Data Guardian has nevertheless urged ministers to give substantial weight to public and professional confidence when evaluating suppliers handling health information.

The debate is not limited to the nationality of the technology provider. A platform supplied by a British company could create similar switching difficulties if NHS organisations became dependent on proprietary applications, interfaces, or data structures that could not easily be transferred elsewhere.

Some MPs have therefore advocated stronger national data standards and more modular technology arrangements, allowing NHS bodies to select different software without rebuilding the information systems connecting them.

Those ideas are relevant to the proposed replacement procurement, although the government has not published a final specification or selected an alternative architecture. A future competition could retain an integrated platform, divide responsibilities between suppliers, or place greater emphasis on interoperability.

Each approach would involve different trade-offs between coordination, supplier flexibility, implementation cost, and accountability for maintaining services.

The December decision will not settle the longer term

The reported preference for extending Palantir would preserve the existing platform while officials consider a successor arrangement. It would also continue the current supplier relationship, making the use of any additional period important to the government’s wider objectives.

Testing alternative systems, documenting dependencies, and evaluating existing applications could improve the feasibility of future competition. Without that preparation, a later procurement could face the same risks that make immediate replacement difficult.

The existing contract must also be reviewed through the appropriate procurement and contractual processes. Even if a successor competition seeks to support UK technological capability, procurement rules would not automatically prevent Palantir from submitting another bid.

Ministers have yet to confirm an extension, announce a future tender, or identify replacement suppliers. The decision required by December 2026 will determine whether the current arrangement continues beyond March 2027, while the longer-term questions of interoperability, service performance, and supplier independence remain unresolved.